1
A critical need
Antibody Innovation Is Not the Bottleneck. Infrastructure Is.
Today’s pharmaceutical and academic communities generate world-class antibody and protein discoveries, yet too many promising programs stall before reaching the clinic.
Why?
-
Limited access to fit-for-purpose pre-GMP processing infrastructure
-
Fragmented and insufficient early-stage CMC expertise
-
CDMOs structured for late-stage manufacturing rather than early innovation
-
Sequential development models that introduce avoidable delays
The consequences are substantial: 6–18 months of lost time, increased burn rates, founder dilution, reduced valuation leverage, and often the need to license programs abroad. There is a clear and urgent infrastructure gap and ExpediteBio is purpose-built to close it.
2
Faster, affordable, smarter, together
BRIDGING THE GAP WITH EXPEDITEBIO
ExpediteBio is specifically designed for academic spinouts, biotech companies, oncology innovators, and venture-backed therapeutic startups seeking to bridge early- and mid-stage R&D with clinical-stage validation. We provide:
-
Dedicated infrastructure and expert CMC support
-
Parallel, risk-based CMC execution
-
Early regulatory alignment and access to a European biohub of industrial and academic expertise
-
Fit-for-purpose Phase-0 processes and directly scalable for further clinical and commercial manufacture
-
A unique GMP-sim and GMP platform technology that eliminates the need for engineering runs and complex technology transfer and or scale-up activities
3
Your benefit
TIMELINES REDUCED BY QUARTERS AND YEARS
In the conventional antibody development pathway, key activities such as cell line development, process and analytical development, engineering runs, technology transfer, and GMP manufacturing, are performed mainly in sequence with large gaps inbetween. This linear approach typically results in a 24 month or more timeline to reach Phase I.
ExpediteBio transforms this model by running cell line development, upstream and downstream process development, and analytical development in parallel within a structured, risk-based framework using an innovative platform. This integrated approach enables direct Phase-0 readiness and accelerates entry into Phase I by 6 to 12 months.
With this acceleration you benefit from a longer financial runway, reduced capital requirements, earlier clinical validation, improved fundraising and valuation potential, and the ability to retain both scientific and economic value within Europe.
